CVS Health Positioned for Growth in 2026 and Beyond
CVS Health Corporation, a key player in the U.S. healthcare sector, oversees a broad array of operations including Aetna, its insurance arm, Caremark, a pharmacy benefits manager, and roughly 9,000 retail pharmacies. As we move into 2026, CVS is navigating past challenges towards more stable growth, evident in its financial performance.
For the full year 2025, CVS reported adjusted earnings per share of $6.75, exceeding expectations despite contending with high medical costs, pressures on Medicare Advantage rates, and evolving Medicaid membership dynamics. A significant milestone in 2025 was the $2.6 billion enhancement in adjusted operating income for Aetna's Health Care Benefits segment. This bolstered profitability and brought the segment's margins closer to target, as noted by CEO David Joyner.
The Centers for Medicare & Medicaid Services (CMS) announced a 2.48% increase in average payment rates for Medicare Advantage plans for 2027, leading to a notable rise in CVS shares. Concurrently, Aetna reported advancements in streamlining its AI-driven prior authorization processes, with a substantial proportion of requests processed rapidly, enhancing regulatory compliance efficiencies.
In March, CVS debuted its first pharmacy-only store in Chicago, with further openings planned for 2026. This initiative aims to deliver pharmacist-led care in smaller, community-focused formats. The Pharmacy and Consumer Wellness division closed 2025 with a 4.5% rise in adjusted operating income, signaling at least stable earnings ahead.
Additionally, CVS reached a proposed settlement with the Federal Trade Commission concerning insulin pricing, resolving regulatory issues impacting its pharmacy benefits operations. The company forecasts an adjusted EPS between $7 and $7.20 for 2026, with a revised operating cash flow of at least $9 billion.
Analysts are observing potential undervaluation of CVS Health stock, citing expected earnings recovery from $5.42 in 2024 to an anticipated $8 by 2027. The company's positive performance has led 18 out of 27 analysts to rate CVS Health as a Buy, expecting further gains if Medicare Advantage margins continue to improve.
CVS Health is positioned for growth with a projected revenue compound annual growth rate of approximately 4% through 2030 and an increasing net income margin. Despite uncertainties in the healthcare cost landscape, the forthcoming Q1 2026 earnings report will be crucial in confirming sustainable growth trends and guiding future expectations.